Computerised decision support for poorly-controlled type 2 diabetes mellitus in Irish General Practice

Supporting General Practitioners intensify medications for patients with poorly-controlled type 2 diabetes mellitus with computerised decision support: a cluster randomised controlled trial in Irish General Practice (the DECIDE study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN69498919

Enrollment

300

Registered

2017-07-26

Start date

2018-10-01

Completion date

Unknown

Last updated

2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Poorly controlled type 2 diabetes mellitus (T2DM) Nutritional, Metabolic, Endocrine Type 2 diabetes mellitus

Interventions

A theory-based complex intervention to target GPs’ prescribing behaviour in the treatment of patients with poorly controlled T2DM was developed using the first stage of the UK Medical Research Council

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: GPs will be the target of the intervention and will be unit of randomisation. All GPs who are part of the HRB Clinical Trials Network will be eligible for inclusion. 1. Only patients with poorly controlled T2DM will be targeted by the GP with the DECIDE intervention 2. Patients must have a diagnosis of T2DM 3. They must be aged over 18 years and less than 75, as there is less evidence about treatment intensification in patients aged above 75 years 4. There is no validated cut-off which defines poor control of T2DM for targeted interventions. For the purposes of this study, the trialists have selected HbA1C or BP levels for which there would be consensus on the importance of intervention and treatment and have clinical face validity in terms of intervention. In the DECIDE study only patients with a HbA1c reading of 8.5% (70 mmol/mol) or above and/or a blood pressure reading over 150/95mmHg will be included 5. Not all patients will be suitable for treatment intensification and individual decisions on treatment changes will be made by each patient’s GP.

Exclusion criteria

Exclusion criteria: 1. All GPs will be included 2. Patients are excluded if they do not fulfill the inclusion criteria

Design outcomes

Primary

Measure	Time frame
HbA1c, a measure of glycaemic control, collected from medical records at baseline and at 6 months follow up	—

Secondary

Measure	Time frame
Medications, blood pressure and lipids collected from medical records at baseline and at 6 months follow up	—

Countries

Ireland

Contacts

Public ContactMark Murphy

markmurphy@rcsi.ie+353 (0)1402 8504

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 23, 2026